HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

INNOGEN-B

3.990

+0.0501.27%

Volume:15.60M

Turnover:61.69M

Market Cap:1.82B

PE:-4.32

High:4.150

Open:3.950

Low:3.800

Close:3.940

52wk High:48.360

52wk Low:3.435

Shares:457.00M

HK Float Shares:420.29M

Volume Ratio:0.85

T/O Rate:3.71%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.923

ROE:-41.16%

ROA:-20.15%

PB:1.66

PE(LYR):-4.32

PS:10.18

Loading ...

Overview Company News Filings

Innogen Pharmaceutical posts 2025 maiden revenue of RMB131.51 million; net loss widens on surging R&D and commercial spend

Bulletin Express

Guangzhou Innogen Pharmaceutical - Plans to Enter the Latin America Market

THOMSON REUTERS

Guangzhou Innogen Pharmaceutical - FY Revenue RMB131.5 Mln

THOMSON REUTERS

Guangzhou Innogen launches esupaglutide α for T2D in China, posting CNY 132 million in 2025 revenue

Guangzhou Innogen FY2025 net loss widens 95.4% to RMB341 million as selling and distribution expenses surge to RMB177 million

Innogen Pharmaceutical revises corporate secretarial lineup, obtains continued waiver under HKEX Listing Rules

Bulletin Express

INNOGEN-B (02591) Appoints Mak Po Man as Joint Company Secretary

Guangzhou Innogen appoints Mak Po Man Cherie as joint company secretary, replacing Sze Suet Ling

INNOGEN-B Shares Drop Over 5% Intraday as Annual Loss Expected to Reach Approximately 341.4 Million Yuan

BRIEF-Guangzhou Innogen Pharmaceutical Expects RMB341.4 Million Loss For Year

Innogen Pharmaceutical Forecasts Wider 2025 Loss

MT Newswires Live

INNOGEN-B Issues Profit Warning, Anticipates 2025 Loss of Approximately RMB 341.4 Million

Guangzhou Innogen expects FY2025 loss of RMB341.4 million

Guangzhou Innogen Pharmaceutical Group Co Ltd - Expected FY Results Due to Increase in Research & Development Expenses of RMB103.3 Mln, Others

THOMSON REUTERS

Guangzhou Innogen Pharmaceutical - Expects RMB341.4 Mln Loss for Year

THOMSON REUTERS

Innogen Pharma Eyes Hong Kong-Listed Share Full Circulation

MT Newswires Live

INNOGEN-B (02591) Plans to Implement H-Share Full Circulation Scheme

Guangzhou Innogen files with CSRC to convert domestic unlisted shares into H shares for Hong Kong listing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/02591/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02591","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"INNOGEN-B","latestPrice":3.99,"timestamp":1789114135003,"preClose":3.94,"halted":0,"volume":15600200,"delay":0,"changeRate":0.012690355329949306,"floatShares":420285370,"shares":457000000,"eps":-0.923422001944854,"marketStatus":"Closed","change":0.05,"latestTime":"09-11 16:08:55","open":3.95,"high":4.15,"low":3.8,"amount":61693850,"amplitude":0.088832,"askPrice":3.995,"askSize":17600,"bidPrice":3.99,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":-0.8611260834718781,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":3.94,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":0.848937,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","floatShares":420285370,"roa":"-20.15%","roe":"-41.16%","lyrEps":-0.923422,"volumeRatio":0.848937,"shares":457000000,"dividePrice":0,"high":4.15,"amplitude":0.088832,"preClose":3.94,"low":3.8,"week52Low":3.435,"pbRate":"1.66","psRate":"10.18","week52High":48.36,"institutionHeld":0,"latestPrice":3.99,"committee":-0.430894,"eps":-0.923422001944854,"divideRate":0,"volume":15600200,"delay":0,"ttmEps":-0.8611260834718781,"open":3.95,"prevYearClose":30.64,"prevWeekClose":3.595,"prevMonthClose":3.635,"prevQuarterClose":7.09,"fiveDayClose":3.595,"twentyDayClose":6.61,"sixtyDayClose":8.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02591\",params:#limit:5,,,undefined,":[{"date":"2026-08-25","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787621400000,"name":null,"time":"","dateTimestamp":1787587200000,"actualEps":null},{"market":"HK","date":"2026-03-23","symbol":"02591","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-29","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02591\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02591\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1775750400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02591\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02591","date":"2026-09-10","current":-4.633468,"percent":0.961832,"low":-137.156472,"twenty":-67.181897,"median":-47.457665,"eighty":-11.394498,"high":-4.018047,"avg":-43.515741,"sd":30.578766,"marketCap":1799868235},"quantilePoints":[{"date":"2025-08-15","current":-137.156472,"twenty":-137.156472,"median":-137.156472,"eighty":-137.156472,"marketCap":26152907730},{"date":"2025-08-22","current":-127.373977,"twenty":-129.344203,"median":-127.373977,"eighty":-126.417438,"marketCap":24211425497},{"date":"2025-08-29","current":-106.390102,"twenty":-127.373977,"median":-126.095992,"eighty":-114.007182,"marketCap":20319324643},{"date":"2025-09-05","current":-78.151342,"twenty":-127.373977,"median":-117.586994,"eighty":-99.491273,"marketCap":18939730209},{"date":"2025-09-12","current":-83.843855,"twenty":-126.417438,"median":-105.433356,"eighty":-83.374192,"marketCap":20355870191},{"date":"2025-09-19","current":-79.271387,"twenty":-126.095992,"median":-93.890147,"eighty":-81.90749,"marketCap":19232094592},{"date":"2025-09-26","current":-78.986763,"twenty":-125.916102,"median":-85.498552,"eighty":-79.429082,"marketCap":19113321562},{"date":"2025-10-03","current":-76.5387,"twenty":-122.116665,"median":-83.843855,"eighty":-78.76383,"marketCap":18565138343},{"date":"2025-10-10","current":-69.068341,"twenty":-116.871032,"median":-83.374192,"eighty":-77.810518,"marketCap":16728724560},{"date":"2025-10-17","current":-67.838616,"twenty":-109.436934,"median":-79.738352,"eighty":-74.826182,"marketCap":16418087403},{"date":"2025-10-24","current":-59.813644,"twenty":-105.816054,"median":-79.429082,"eighty":-68.576451,"marketCap":14481173363},{"date":"2025-10-31","current":-57.61442,"twenty":-103.460611,"median":-78.986763,"eighty":-66.346017,"marketCap":13969535692},{"date":"2025-11-07","current":-56.556997,"twenty":-100.097405,"median":-78.243448,"eighty":-63.14919,"marketCap":13704580470},{"date":"2025-11-14","current":-61.96171,"twenty":-95.010372,"median":-77.299283,"eighty":-61.326336,"marketCap":15056765743},{"date":"2025-11-21","current":-54.467459,"twenty":-87.179427,"median":-75.823033,"eighty":-60.1184,"marketCap":13229488347},{"date":"2025-11-28","current":-82.342484,"twenty":-85.508442,"median":-76.5387,"eighty":-60.703449,"marketCap":20072642195},{"date":"2025-12-05","current":-82.313405,"twenty":-85.248884,"median":-75.823033,"eighty":-61.326336,"marketCap":20100051356},{"date":"2025-12-12","current":-63.824496,"twenty":-84.462171,"median":-74.404407,"eighty":-61.326336,"marketCap":15614085348},{"date":"2025-12-19","current":-62.072323,"twenty":-83.725798,"median":-74.049705,"eighty":-60.286674,"marketCap":15221220708},{"date":"2025-12-24","current":-59.762449,"twenty":-83.548712,"median":-73.276127,"eighty":-59.816947,"marketCap":14700446650},{"date":"2026-01-02","current":-56.27243,"twenty":-83.409096,"median":-71.366231,"eighty":-59.572219,"marketCap":13896444596},{"date":"2026-01-09","current":-57.1291,"twenty":-82.548826,"median":-69.803372,"eighty":-58.239982,"marketCap":14143127045},{"date":"2026-01-16","current":-56.980838,"twenty":-82.319221,"median":-67.499105,"eighty":-57.682607,"marketCap":14152263432},{"date":"2026-01-23","current":-58.213825,"twenty":-82.096799,"median":-66.291021,"eighty":-57.601428,"marketCap":14444627815},{"date":"2026-01-30","current":-54.613459,"twenty":-81.934522,"median":-64.906051,"eighty":-57.510573,"marketCap":13613216600},{"date":"2026-02-06","current":-49.064319,"twenty":-80.235292,"median":-63.834,"eighty":-57.242442,"marketCap":12261031327},{"date":"2026-02-13","current":-50.165477,"twenty":-79.691019,"median":-62.941647,"eighty":-57.039695,"marketCap":12608214032},{"date":"2026-02-20","current":-50.419859,"twenty":-79.623791,"median":-62.643943,"eighty":-56.891323,"marketCap":12653895967},{"date":"2026-02-27","current":-50.052949,"twenty":-79.470699,"median":-62.017016,"eighty":-56.651056,"marketCap":12699577902},{"date":"2026-03-06","current":-43.88908,"twenty":-79.397543,"median":-60.902753,"eighty":-56.29247,"marketCap":11045891858},{"date":"2026-03-13","current":-39.965904,"twenty":-79.214462,"median":-60.292057,"eighty":-54.71959,"marketCap":10104843999},{"date":"2026-03-20","current":-39.174717,"twenty":-78.964109,"median":-59.813644,"eighty":-50.865048,"marketCap":9867297938},{"date":"2026-03-27","current":-24.701097,"twenty":-78.775514,"median":-59.491697,"eighty":-50.290678,"marketCap":9547524394},{"date":"2026-04-02","current":-24.535908,"twenty":-78.383597,"median":-58.823921,"eighty":-50.052949,"marketCap":9529251620},{"date":"2026-04-10","current":-24.978414,"twenty":-78.348547,"median":-58.584467,"eighty":-49.631191,"marketCap":9775934068},{"date":"2026-04-17","current":-23.474521,"twenty":-78.227102,"median":-58.112982,"eighty":-48.421657,"marketCap":9191205301},{"date":"2026-04-24","current":-19.658213,"twenty":-78.155492,"median":-57.844151,"eighty":-44.116877,"marketCap":7697406030},{"date":"2026-04-30","current":-16.329046,"twenty":-77.825679,"median":-57.660489,"eighty":-41.074266,"marketCap":6395470886},{"date":"2026-05-08","current":-17.822364,"twenty":-77.322024,"median":-57.626503,"eighty":-40.478309,"marketCap":5778764764},{"date":"2026-05-15","current":-17.368107,"twenty":-77.157551,"median":-57.517602,"eighty":-40.012158,"marketCap":5646287153},{"date":"2026-05-22","current":-17.112125,"twenty":-76.782452,"median":-57.446424,"eighty":-25.37304,"marketCap":5550355090},{"date":"2026-05-29","current":-15.607197,"twenty":-76.252433,"median":-57.23775,"eighty":-24.916387,"marketCap":5079831160},{"date":"2026-06-05","current":-14.014909,"twenty":-75.020932,"median":-57.073515,"eighty":-24.414835,"marketCap":4568193490},{"date":"2026-06-12","current":-11.752443,"twenty":-74.621039,"median":-56.924891,"eighty":-23.900197,"marketCap":3828146144},{"date":"2026-06-18","current":-10.549084,"twenty":-74.404407,"median":-56.73827,"eighty":-23.474521,"marketCap":3444417891},{"date":"2026-06-26","current":-9.60263,"twenty":-74.160764,"median":-56.642046,"eighty":-20.865982,"marketCap":3120076153},{"date":"2026-07-03","current":-11.351574,"twenty":-74.088566,"median":-56.533624,"eighty":-19.581214,"marketCap":3691100339},{"date":"2026-07-10","current":-11.238926,"twenty":-74.037218,"median":-56.208644,"eighty":-19.055481,"marketCap":3649986598},{"date":"2026-07-17","current":-10.540302,"twenty":-73.42668,"median":-55.144116,"eighty":-17.753872,"marketCap":3435281504},{"date":"2026-07-24","current":-10.636027,"twenty":-71.947117,"median":-53.621015,"eighty":-17.028947,"marketCap":3467258858},{"date":"2026-07-31","current":-10.1543,"twenty":-71.465685,"median":-51.153424,"eighty":-16.590446,"marketCap":3316508473},{"date":"2026-08-07","current":-10.609247,"twenty":-70.999854,"median":-50.412223,"eighty":-15.817726,"marketCap":3471827052},{"date":"2026-08-14","current":-9.215586,"twenty":-70.625283,"median":-50.222782,"eighty":-14.020929,"marketCap":3019575896},{"date":"2026-08-21","current":-5.675745,"twenty":-69.656366,"median":-50.052949,"eighty":-12.083492,"marketCap":1863822943},{"date":"2026-08-28","current":-4.445704,"twenty":-68.330506,"median":-49.617462,"eighty":-11.852702,"marketCap":1733629429},{"date":"2026-09-04","current":-4.209722,"twenty":-67.634909,"median":-49.247121,"eighty":-11.642751,"marketCap":1642265559},{"date":"2026-09-10","current":-4.607496,"twenty":-67.181897,"median":-47.457665,"eighty":-11.394498,"marketCap":1799868235}],"updateTime":1789119320004},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02591\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1190961010","title":"Innogen Pharmaceutical posts 2025 maiden revenue of RMB131.51 million; net loss widens on surging R&D and commercial spend","url":"https://stock-news.laohu8.com/highlight/detail?id=1190961010","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190961010?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:02","pubTimestamp":1774278135,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group (Innogen-B) released its first post-IPO annual results, highlighting the transition from pure R&D to simultaneous development and commercialisation. Revenue and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621870210","title":"Guangzhou Innogen Pharmaceutical - Plans to Enter the Latin America Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2621870210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621870210?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:55","pubTimestamp":1774277747,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0AT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621021447","title":"Guangzhou Innogen Pharmaceutical - FY Revenue RMB131.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621021447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621021447?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:55","pubTimestamp":1774277747,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0AT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702129","title":"Guangzhou Innogen launches esupaglutide α for T2D in China, posting CNY 132 million in 2025 revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702129","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702129?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:55","pubTimestamp":1774277731,"startTime":"0","endTime":"0","summary":"Innogen reported the China approval and commercial launch of its core product, yisupaglutide α, for adult type 2 diabetes, marking a shift toward a combined R&D-and-commercial model.National reimbursement listing for the adult type 2 diabetes indication is scheduled to take effect on Jan. 1, 2026, which may expand patient access and support broader hospital uptake.The company said it is pursuing lifecycle expansion into weight management and MASH, targeting additional revenue streams beyond the initial diabetes market.Overseas filings were submitted in Hong Kong and selected markets in Southeast Asia and Latin America, positioning the product for potential regional commercialization partnerships.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL4htKm7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702126","title":"Guangzhou Innogen FY2025 net loss widens 95.4% to RMB341 million as selling and distribution expenses surge to RMB177 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702126","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702126?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:55","pubTimestamp":1774277727,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen FY2025 net loss widens 95.4% to RMB341 million as selling and distribution expenses surge to RMB177 million. Innogen published an annual results announcement for the year ended Dec. 31, 2025.Revenue was RMB131.5 million, while gross profit was RMB117.1 million.Loss for the year widened to RMB341.4 million, and basic and diluted loss per share was RMB0.79.Research and development expenses rose 100.7% to RMB205.8 million, driven by higher pre-clinical and clinical trial and process optimization fees and higher raw materials costs tied to Efsubaglutide Alfa.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via II","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL6kt3KB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180017707","title":"Innogen Pharmaceutical revises corporate secretarial lineup, obtains continued waiver under HKEX Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=1180017707","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180017707?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:23","pubTimestamp":1774268588,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) announced several governance adjustments effective 23 March 2026. Joint Company Secretary Sze Suet Ling will resign from her...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112376071","title":"INNOGEN-B (02591) Appoints Mak Po Man as Joint Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=1112376071","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112376071?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:10","pubTimestamp":1774267820,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) announced that Ms. Shi Xueling has resigned from her positions as (i) Joint Company Secretary of the Company, (ii) the Company's Authorized Representative for accepting service of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621703329","title":"Guangzhou Innogen appoints Mak Po Man Cherie as joint company secretary, replacing Sze Suet Ling","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703329","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703329?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:05","pubTimestamp":1774267514,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen said Suet Ling Sze resigned as joint company secretary, agent for service of process, and authorized representative, effective March 23, 2026.Mak is vice president of SWCS Corporate Services Group  and has over 20 years of experience in audit, accounting, corporate finance, compliance, and corporate secretarial work.Dongyan Yang will continue as the other joint company secretary and has served as the group’s legal director since April 2021.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 23, 2026, and is solely respon","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL97VtGk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163444545","title":"INNOGEN-B Shares Drop Over 5% Intraday as Annual Loss Expected to Reach Approximately 341.4 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1163444545","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163444545?lang=en_us&edition=fundamental","pubTime":"2026-03-20 11:57","pubTimestamp":1773979053,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) fell more than 5% during trading, and as of the latest update, the decline was 2.17%, with the share price at HK$21.62 and a turnover of HK$3.98 million. On March 18, the company...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1161","02591","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232743","title":"BRIEF-Guangzhou Innogen Pharmaceutical Expects RMB341.4 Million Loss For Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232743","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232743?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:53","pubTimestamp":1773831220,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Innogen Pharmaceutical Expects RMB341.4 Million Loss For YearMarch 18  - Guangzhou Innogen Pharmaceutical Group Co Ltd 2591.HK:EXPECTS RMB341.4 MILLION LOSS FOR YEAREXPECTED FY RESULTS DUE TO INCREASE IN RESEARCH & DEVELOPMENT EXPENSES OF  RMB103.3 MILLION, OTHERSFurther company coverage: 2591.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4050WH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620383236","title":"Innogen Pharmaceutical Forecasts Wider 2025 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2620383236","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620383236?lang=en_us&edition=fundamental","pubTime":"2026-03-18 16:56","pubTimestamp":1773824180,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  expects a net loss of about 341.4 million yuan for 2025, widening from a loss of about 174.7 million yuan a year earlier, according to a Wednesday Hong Kong bourse filing.The pharmaceutical company said the wider loss was mainly due to higher research and development spending and increased selling and distribution expenses related to the product's launch and sales expansion.The company is expected to announce financial results on March 23.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171204323","title":"INNOGEN-B Issues Profit Warning, Anticipates 2025 Loss of Approximately RMB 341.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1171204323","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171204323?lang=en_us&edition=fundamental","pubTime":"2026-03-18 16:41","pubTimestamp":1773823269,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) announced that despite generating revenue of approximately RMB 131.5 million in 2025 (2024: zero) following the commercial launch of its core product, Eisupaglutide α, for the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620356022","title":"Guangzhou Innogen expects FY2025 loss of RMB341.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620356022","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620356022?lang=en_us&edition=fundamental","pubTime":"2026-03-18 16:35","pubTimestamp":1773822904,"startTime":"0","endTime":"0","summary":"Innogen expects a loss of about RMB341.4 million for the year ended 31 December 2025, compared with a loss of about RMB174.7 million a year earlier. The company recorded revenue of about RMB131.5 million in 2025, versus nil in 2024, following the commercialization of Efsubaglutide Alfa for type 2 diabetes in China and Macau. Innogen said research and development expenses rose by about RMB103.3 million, driven by higher spending on raw materials, pre-clinical studies, clinical trials and process optimization related to Efsubaglutide Alfa. It also reported an increase in selling and distribution expenses of about RMB174.3 million, mainly due to higher marketing and promotional costs and expanded sales staffing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6NyZPh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620235673","title":"Guangzhou Innogen Pharmaceutical Group Co Ltd - Expected FY Results Due to Increase in Research & Development Expenses of  RMB103.3 Mln, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2620235673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620235673?lang=en_us&edition=fundamental","pubTime":"2026-03-18 16:34","pubTimestamp":1773822894,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4050WH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620235627","title":"Guangzhou Innogen Pharmaceutical - Expects RMB341.4 Mln Loss for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2620235627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620235627?lang=en_us&edition=fundamental","pubTime":"2026-03-18 16:34","pubTimestamp":1773822894,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4050WH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620242400","title":"Innogen Pharma Eyes Hong Kong-Listed Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2620242400","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620242400?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:29","pubTimestamp":1773750578,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  submitted a filing application for the proposed conversion of all its domestic unlisted shares into Hong Kong-listed shares to the China Securities Regulatory Commission, a Tuesday Hong Kong bourse filing said.The firm also intends to apply for the listing of, and permission to deal in, the converted shares on the Main Board of the Hong Kong Stock Exchange.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172970710","title":"INNOGEN-B (02591) Plans to Implement H-Share Full Circulation Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1172970710","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172970710?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:40","pubTimestamp":1773744032,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) announced that on March 17, 2026, the company submitted an application to the China Securities Regulatory Commission for the proposed conversion of all its domestic unlisted shares...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620547425","title":"Guangzhou Innogen files with CSRC to convert domestic unlisted shares into H shares for Hong Kong listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2620547425","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620547425?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:37","pubTimestamp":1773743875,"startTime":"0","endTime":"0","summary":"Innogen said it has submitted a filing application for the proposed conversion of all its domestic unlisted shares into H shares. The company plans to apply for the listing of, and permission to deal in, the converted H shares on the Hong Kong Stock Exchange’s Main Board. Innogen said the filing procedures are not yet complete and the implementation plan has not been finalised. It added that no shareholders’ meeting is required to approve the conversion and listing under its articles of association.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL49NV01:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":118,"code":"91000000","status":"200"}]}}